Resultados da pesquisa - Scott, Rob

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism Por Chan, Dick C., Watts, Gerald F., Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Barrett, P. Hugh R.

Obter o texto integral Obter o texto integral Obter o texto integral

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab Por Desai, Nihar R., Giugliano, Robert P., Wasserman, Scott M., Gibbs, John P., Liu, Thomas, Scott, Rob, Sabatine, Marc S.

Obter o texto integral Obter o texto integral Obter o texto integral

Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hyperc... Por Cho, Leslie, Rocco, Michael, Colquhoun, David, Sullivan, David, Rosenson, Robert S., Dent, Ricardo, Xue, Allen, Scott, Rob, Wasserman, Scott M, Stroes, Erik

Obter o texto integral Obter o texto integral Obter o texto integral

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Par... Por Kohli, Payal, Ganz, Peter, Ma, Yifei, Scherzer, Rebecca, Hur, Sophia, Weigel, Bernard, Grunfeld, Carl, Deeks, Steven, Wasserman, Scott, Scott, Rob, Hsue, Priscilla Y.

Obter o texto integral Obter o texto integral Obter o texto integral

Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hy... Por Robinson, Jennifer G., Rogers, William J., Nedergaard, Bettina S., Fialkow, Jonathan, Neutel, Joel M., Ramstad, David, Somaratne, Ransi, Legg, Jason C., Nelson, Patric, Scott, Rob, Wasserman, Scott M., Weiss, Robert

Obter o texto integral Obter o texto integral Obter o texto integral

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role Por Raal, Frederick J., Giugliano, Robert P., Sabatine, Marc S., Koren, Michael J., Blom, Dirk, Seidah, Nabil G., Honarpour, Narimon, Lira, Armando, Xue, Allen, Chiruvolu, Padmaja, Jackson, Simon, Di, Mei, Peach, Matthew, Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Stein, Evan A.

Obter o texto integral Obter o texto integral Obter o texto integral

Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subj... Por Nissen, Steven E., Dent‐Acosta, Ricardo E., Rosenson, Robert S., Stroes, Erik, Sattar, Naveed, Preiss, David, Mancini, G.B. John, Ballantyne, Christie M., Catapano, Alberico, Gouni‐Berthold, Ioanna, Stein, Evan A., Xue, Allen, Wasserman, Scott M., Scott, Rob, Thompson, Paul D.

Obter o texto integral Obter o texto integral Obter o texto integral